Caffeine Citrate is generally applied in the management of specific respiratory challenges in premature infants. It is considered relevant for the treatment of primary apnea of premature newborns (AOP). The medication is used for managing the symptom cluster of prolonged pauses in breathing and the associated slowed heart rate (bradycardia).

The medicine is considered relevant within supportive care for low birth weight and premature neonates within the Neonatal Intensive Care Unit (NICU). It is applied in addressing symptoms of central nervous system sluggishness and respiratory instability, which are conditions where symptoms may intensify temporarily. By promoting consistent and stable breathing patterns, this medication contributes to improved comfort during symptomatic periods, helping to ease the overall symptom load.

Quick Fact: Symptomatic support for Apnea of Prematurity
This supportive medicine is applied in addressing symptoms that create noticeable physiological strain in infants born too early.

Caffeine Citrate has a highly specific eligibility profile defined by regulatory bodies. The medicine is indicated only for preterm infants between 28 and <33 weeks gestational age for the short-term treatment of primary apnea of prematurity. Eligibility is conditional: all other causes of apnea, such as sepsis or central nervous system disorders, must be ruled out prior to treatment initiation.

The only absolute exclusion, or contraindication, for this medicine is a demonstrated hypersensitivity to any of the product's components.

Use is not established for populations outside the neonatal range, including older children, adults, or geriatric patients. Furthermore, safety and efficacy have not been established for treatment periods longer than the initial course.

Regulatory documents require caution and monitoring when the medicine is administered to infants with impaired renal or hepatic function, or those with pre-existing cardiovascular disease or seizure disorders. Special consideration applies to breastfeeding mothers, who are officially advised to not ingest caffeine-containing products to prevent potential drug accumulation in the infant.

Interactions with other medicines and products

The official regulatory profile for Caffeine Citrate is structured around documented pharmacokinetic and pharmacodynamic interactions, which are critical due to the sensitive patient population. Interactions are primarily governed by the drug's metabolism and its classification as a methylxanthine.

Interactions Affecting Exposure (Pharmacokinetic)

Caffeine is mainly cleared via the Cytochrome P450 1A2 (CYP1A2) enzyme. Co-administration with substances that inhibit or induce this enzyme is officially documented to alter the plasma concentration of caffeine. Medicines classified as CYP1A2 inhibitors, such as Cimetidine and Ketoconazole, decrease clearance, potentially leading to increased exposure. Conversely, CYP1A2 inducers, including Phenobarbital and Phenytoin, increase clearance, potentially reducing exposure.

Interactions Affecting Effect (Pharmacodynamic)

Concurrent use with other methylxanthines, particularly Theophylline, is formally discouraged by regulatory authorities due to the risk of additive pharmacological effects and competitive clearance mechanisms. Additionally, the co-administration of gastric acid-suppressing medicinal products is a documented consideration due to a potential association with an increased risk of necrotising enterocolitis.

Population-Specific Constraints

In preterm neonates who were previously treated with Theophylline or whose mothers consumed high quantities of caffeine, regulatory documents require the measurement of baseline plasma caffeine concentrations before initiating treatment. This ensures proper management of potential accumulation.

Adenosine Receptor Antagonism

Caffeine Citrate's active component, caffeine, acts primarily by competitively blocking adenosine receptors (A1 and A2A), antagonizing the inhibitory action of adenosine on neural activity. This mechanism disinhibits the release of excitatory neurotransmitters, which results in the overall stimulant profile.

---

Central Neural Respiratory Stimulation

The disinhibition of neural activity is concentrated in the medullary respiratory centers in the brainstem, which regulate the respiratory cycle. This action stimulates the central respiratory drive and increases the body's sensitivity to carbon dioxide ( CO2), resulting in an alteration of minute ventilation (rate and depth of breathing).

---

Systemic Signaling and Cardiopulmonary Effects

Beyond the CNS, caffeine's action contributes to systemic effects. At higher concentrations, it causes non-selective inhibition of phosphodiesterase (PDE) enzymes, which raises intracellular signaling molecules (cAMP). This, along with general adenosine receptor antagonism, contributes to systemic effects, including changes in myocardial contractility (inotropic) and heart rate (chronotropic), and contributes to the systemic stimulatory and smooth muscle-relaxing actions.

Caffeine Citrate is administered using a structured two-phase regimen, strictly within a Neonatal Intensive Care Unit (NICU) under the supervision of a physician experienced in neonatology. The standardized approach ensures precise, weight-based administration to premature infants.

Administration Details and Dosage Protocol

The medicine is supplied as a sterile, aqueous solution, with doses calculated in milligrams of the caffeine citrate salt (e.g., 20 mg/mL solution). Dosing is always calculated based on the infant’s body weight (mg/kg).

Administration Phase	Dose (Caffeine Citrate)	Route and Timing	Procedural Requirement
Loading Dose	20 mg/kg (single dose)	Intravenous (IV) Infusion	Must be infused slowly over 30 minutes.
Maintenance Dose	5 mg/kg/day	IV Infusion or Oral (PO) (via feeding tube)	Given once daily, starting 24 hours after the loading dose.

Maintenance dosing may be increased up to 10 mg/kg/day if the response is insufficient, and IV maintenance doses are administered over a shorter time of 10 to 15 minutes. The solution can be administered undiluted or diluted in compatible sterile solutions (such as 0.9% sodium chloride) immediately before use.

Duration and Discontinuation

Treatment is typically continued until the infant reaches a clinical stability milestone, such as remaining free of clinically significant apnea for five to seven days, or reaching approximately 37 weeks post-menstrual age. Critically, if the infant has impaired renal function, the daily maintenance dose must be reduced to prevent accumulation. Official instructions also state that no dose tapering is required when the medicine is discontinued.

Research evidence / Overview of studies for Caffeine Citrate

Evidence for Primary Apnea of Prematurity (AOP)

Research regarding the use of Caffeine Citrate for Primary Apnea of Prematurity (AOP) was studied for in multiple clinical evaluations. These evaluations primarily include short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. Studies explored how the drug was observed in contexts involving fluctuating or unstable symptoms, focusing on very low birth weight infants who experience prolonged pauses in breathing.

Studies monitored how symptoms evolved in the observed populations when the medicine was compared to an inactive substance (placebo) or an alternative treatment like theophylline. Findings describe patterns observed in the studies; research highlights changes measured during the study period related to the frequency of these breathing pauses. Studies also examined the need for aggressive respiratory support, reporting measurements related to the requirement for mechanical ventilation during the initial days of treatment.

---

Evidence for Respiratory Support and Lung Development

A major part of the evidence landscape comes from large-scale international Randomized Controlled Trials, which have focused on very low birth weight infants. These studies explored outcomes related to systemic or functional imbalance, such as the ability to be weaned off supportive breathing machines. Specifically, research examined the incidence of Bronchopulmonary Dysplasia (BPD) (a chronic lung disease), which is a key long-term respiratory outcome.

Findings describe patterns observed in the studies; differences in the duration of mechanical ventilation required by the infants were reported. This evidence contributes to understanding symptom patterns related to long-term respiratory health in this specific, vulnerable population.

---

Long-Term Studies and Neurodevelopmental Follow-up

The research base includes long-term follow-up studies that tracked the progress of infants who participated in the original RCTs for several years after their initial treatment. Studies monitored outcomes up to 18–24 months and 5 years corrected age, evaluating whether initial treatment was associated with differences in long-term outcomes.

These investigations monitored key outcomes, including assessments of long-term survival rates and functional measures of the neurodevelopmental system, such as assessments for cerebral palsy and measures of cognitive function. The findings describe group patterns observed in the studies, providing insight into the overall developmental trajectory of the groups that was evaluated in the medicine versus those who received placebo.

---

What is Still Uncertain About Caffeine Citrate Research

While the research provides considerable insight into short-term changes and long-term developmental patterns, certain gaps and uncertainties remain. Long-term effects are not fully established beyond the 5-year follow-up of the main trials. Research is still ongoing to determine if different dosing strategies, such as higher doses or earlier administration, may yield different outcomes, particularly concerning the incidence of BPD.

Additionally, subgroup findings are uncertain, and study results reflect the specific conditions under which they were conducted. The evidence highlights what is known—and what is still uncertain—about the medicine's use in varying clinical settings.

Common questions about Caffeine Citrate (FAQ)

Q: Is Caffeine Citrate the same as regular caffeine pills or coffee?

A: According to official product information, Caffeine Citrate is a specialized salt formulation that combines caffeine with citric acid. It is specifically designed as a sterile, aqueous solution for precise, controlled medical administration in a hospital setting. Research overviews describe this unique formulation as having a wider therapeutic margin compared to other methylxanthines used for similar purposes.

Q: Can Caffeine Citrate affect sleep patterns?

A: Regulatory documents note that because this medicine is a stimulant, it may cause effects like restlessness and tremor. Product safety information also includes insomnia, or trouble sleeping, as a potential adverse effect related to its central nervous system activity.

Q: Can people with kidney or liver issues use Caffeine Citrate?

A: The medicine can be used with caution in infants who have impaired kidney (renal) or liver (hepatic) function. Official documents require close monitoring of serum caffeine concentrations in these cases. This monitoring is necessary to account for the slower removal of the drug from the body, which is documented to necessitate dose review.

Q: What are the key differences between the oral and intravenous forms of Caffeine Citrate?

A: Both intravenous (IV) and oral solutions are utilized for administration in a hospital setting. The IV maintenance dose is administered over a shorter time. The oral solution is generally administered via a feeding tube and may be given with feeds as a consideration to reduce gastric irritation.

Q: What precautions are advised regarding the storage of Caffeine Citrate?

A: Official labeling advises that the medicine must be stored at controlled room temperature and should not be frozen. Regulatory information emphasizes that the medication must be kept out of the sight and reach of children. The oral solution must always be stored in its child-resistant container.

Q: Can Caffeine Citrate affect other medications that are metabolized by the liver?

A: The active component, caffeine, is primarily broken down by a liver enzyme called CYP1A2. Regulatory information indicates that caffeine has the potential to interact with other medicines that are also substrates (affected by) this same enzyme.

Q: Does taking too much Caffeine Citrate cause severe side effects?

A: Yes, the potential for toxicity (too much medicine in the body) is documented in safety information. Serious toxicity has been reported when serum caffeine levels exceed 50 mg/L, and regulatory information advises seeking immediate medical assistance if symptoms of toxicity are suspected.

Q: Is it okay to use Caffeine Citrate if a person has certain heart conditions?

A: Regulatory documents advise that the medicine should be used with caution in infants with pre-existing cardiovascular disease. This precaution is necessary because caffeine, a stimulant, has the potential to increase heart rate (tachycardia) and blood pressure.

Q: Can the medicine be used if the user has a known allergy to caffeine?

A: Official product information states that the medicine is contraindicated, meaning it should not be used, if a patient has demonstrated hypersensitivity (an allergic reaction) to caffeine itself or any of the product's other components.

Q: What should be done if the person taking the medicine shows signs of intolerance?

A: Regulatory safety information advises that a healthcare provider should be contacted immediately if the patient shows certain signs that may indicate intolerance or serious adverse reactions. These signs include fast heartbeats, restlessness or jitteriness, vomiting, or abdominal swelling.

Q: Are there any food or drinks that should be avoided while using this medicine?

A: Official safety information advises that food or drinks containing caffeine should be avoided for the patient while using this medicine. Furthermore, regulatory documents note that breastfeeding mothers of infants receiving the medicine should avoid the ingestion of caffeine-containing products to prevent potential drug accumulation in the infant.

Q: What is the official safety classification of Caffeine Citrate (e.g., Pregnancy Category)?

A: The medicine is only indicated for use in premature infants. However, for classification purposes, the US Food and Drug Administration (FDA) assigned a Pregnancy Category C, and the Australian Therapeutic Goods Administration (TGA) assigned Category A.

Q: What is meant by the 'therapeutic window' for Caffeine Citrate?

A: Research overviews often mention that this medicine is associated with a wider therapeutic margin compared to other methylxanthines, such as theophylline, that are used for similar purposes.

Q: What happens if a dose is missed?

A: In the event of a missed dose, regulatory patient information instructs the caregiver to contact the healthcare provider for specific instructions. The next dose should not be doubled, as formally stated in patient information.

Q: Is there a common reason for stopping Caffeine Citrate treatment?

A: Treatment is typically discontinued when the infant reaches a clinical stability milestone. This primary reason for cessation is defined as when the infant is free of clinically significant apnea for five to seven days, or reaches approximately 37 weeks post-menstrual age.

Q: Does Caffeine Citrate have any known effects on nutrition or metabolism?

A: According to regulatory documents, the medicine has known effects on nutrition and metabolism. Adverse reaction lists include hyperglycemia (high blood sugar) and feeding intolerance as very common effects.

Q: Are there known interactions with specific antibiotics or antifungals?

A: Yes, the medicine has documented interactions with certain CYP1A2 inhibitor medicines, including some antibiotics and antifungals like Ketoconazole. Co-administration with these types of medicines may decrease the clearance of caffeine from the body.

Q: Why do some official documents mention the possibility of a brain bleed (intracranial hemorrhage)?

A: Intracranial bleeding (brain hemorrhage) is noted in some regulatory-based safety profiles as a severe, but possibly rare, adverse effect. Official product information also advises using the drug with caution in infants with pre-existing seizure disorders.

Q: What are the symptoms of Caffeine Citrate being too high in the body?

A: The presence of too much of the medicine in the body can lead to symptoms such as fever, nervousness, vomiting, abnormal blood tests, and, in severe cases, seizures.

Storage and Disposal of Caffeine Citrate

Caffeine Citrate injection and oral solution must be stored and disposed of according to strict regulatory requirements to maintain product stability and safety.

Official Storage Conditions

The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The official labeling explicitly states that the solution must not be frozen and should be stored in the original container to protect it from light.

Child Safety and Handling

It is mandatory to keep this medicine out of the sight and reach of children. The oral solution must always be stored in its child-resistant container.

Stability and Disposal Requirements

Since the product is supplied in single-use vials and is preservative-free, any unused portion of the solution remaining in an opened vial must be discarded immediately and must not be saved. Expired or unused product must be disposed of according to local regulations and should not be thrown into household trash or poured into wastewater.